Abstract
The role of venture companies has become more important in the pharmaceutical industry. Big pharmas depend on venture companies for the creation of new drugs. The pharmaceutical industry is a typical example of an intellectual industry that combines scientific technologies together. Japan, a country poor in natural resources, promotes the industry as a matter of national policy. However, the public budget for the bio-industry is meager, and the private financial environment is poor. In Japan, bio-venture companies are not well nurtured, due to a lack of public aid for clinical tests and research, a difference that stands out in comparison to the US.
Japan's basic research results are drawing near to clinical applications, so we must decide to invest public funds in clinical research.
